Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

This study is testing a new type of cell therapy called CD40L-augmented TIL — where a patient's own cancer-fighting immune cells (tumor-infiltrating lymphocytes, or TILs) are removed from a tumor, enhanced in the lab, and then infused back into the patient to fight advanced melanoma. This is for people whose melanoma has stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older and have advanced (unresectable stage III/IV) melanoma of any type — including skin, acral (hands/feet), mucosal, or eye melanoma - Your cancer has stopped responding to, or you cannot tolerate, at least one standard treatment (such as anti-PD-1 or BRAF/MEK inhibitors) - You have at least one tumor that can be surgically removed to collect immune cells, and at least one other measurable tumor to track treatment response - You are in good general health (ECOG 0 or 1) - You are willing to use reliable birth control during and after the study **You may NOT be eligible if...** - You have a history of significant heart disease (unless cleared by a cardiac specialist) - You have HIV/AIDS, a primary immune deficiency, or are on immunosuppressive medications (more than 10mg prednisone/day) - You are pregnant or breastfeeding - You have received prior live cell therapy (unless approved by the investigator) - You have active infections requiring antibiotics Talk to your doctor to see if this trial is right for you.